

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復星醫藥（集團）股份有限公司

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

(Stock Code: 02196)

### 2015 THIRD QUARTERLY REPORT

本公司（「公司」）之香港上市地位，乃根據香港證券及期貨條例第13.09(2)條及香港交易所上市規則第13.10B條之規定，由本公司之證券及期貨事務監察委員會（「證監會」）及香港交易所（「交易所」）共同核准。本公司之證券及期貨事務監察委員會（「證監會」）及香港交易所（「交易所」）共同核准。

本公司（「公司」）之香港上市地位，乃根據香港證券及期貨條例第13.09(2)條及香港交易所上市規則第13.10B條之規定，由本公司之證券及期貨事務監察委員會（「證監會」）及香港交易所（「交易所」）共同核准。本公司之證券及期貨事務監察委員會（「證監會」）及香港交易所（「交易所」）共同核准。

陳啟宇  
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*  
Chen Qiyu  
Chairman

2015年9月29日

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of the Company are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

\* for identification purposes only





E ]- ' ] / 4 ] ] - u

: u] C<sub>u</sub> # 3 / : MB

Items	Amounts during the Reporting Period (Jul - Sep 2015)	Amounts from the beginning of the year to the end of the Reporting Period (Jan - Sep 2014)	Description
	97,665,175.84	191,310,773.56	M] u] # 3 / : MB
G			

2.2 The shareholding status of the Top 10 shareholders

73,142

The shareholding status of the Top 10 shareholders						
Name of shareholders (full name)	Shareholding at the end of the period	Percentage (%)	Number of restricted shares held	Shares pledged or locked up		Capacity
				Status	Number	
HANGHAI FOUNDRY HIGH TECHNOLOGY (GROUP) COMPANY LIMITED ("FANGHU")	920,641,314	39.83	0	None	0	Director
HK CCNOMINEE LIMITED (No. 1)	402,619,300	17.42	0	None	0	None
CHINA ECONOMIC FINANCE COMPANY LIMITED	69,112,399	2.99	0	None	0	None
NATIONAL SOCIAL ECONOMIC FOUNDATION 104 FOLIO*	37,199,998	1.61	0	None	0	None
HONGKONG ECONOMIC CLEARING COMPANY LIMITED (No. 2)	33,556,005	1.45	0	None	0	None
CENTRAL HUIJIN INVESTMENT LTD.	24,067,700	1.04	0	None	0	None
INHA LIFE INSURANCE CO., LTD. — DIRECTOR — GENERAL DIRECTOR — 018L — FH001 HANGHAI*	22,652,864	0.98	0	None	0	None
ING CANAL (BEIJING) CO., LTD. — INGCANAL GROUP HOLDING COMPANY LIMITED*	17,695,247	0.77	0	None	0	None
FIDELITY INVESTMENT SERVICES*	16,764,537	0.73	0	None	0	None
INGAN CO., LTD. — ELI INVESTMENT • INGCANAL	16,567,783	0.72	0	None	0	None

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
EG	920,641,314	MB	920,641,314
HK CC NOMINEE LIMITED (Note 1)	402,619,300	MB	402,619,300
CHINA ECIE FINANCE COMPANY LIMITED	69,112,399	MB	69,112,399
NATIONAL SOCIAL ECIFUND 104 FOLIO*	37,199,998	MB	37,199,998
HONG KONG ECIE CLEARING COMPANY LIMITED (Note 2)	33,556,005	MB	33,556,005
CENTRAL HOLDINGS LIMITED	24,067,700	MB	24,067,700
INHA LIFE INSURANCE COMPANY, LTD. — DIRECTOR — G. DIRECTOR — 018L — FH001 HANGHAI*	22,652,864	MB	22,652,864
ING CAPITAL (BEIJING) COMPANY, LTD. — ING CAPITAL GROUP HOLDINGS I*	17,695,247	MB	17,695,247
FIC ING ELECTED I*	16,764,537	MB	16,764,537
ING AN COMPANY, LTD. — ELIEMENTAL ING CAPITAL	16,567,783	MB	16,567,783
		ING CAPITAL (BEIJING) COMPANY, LTD. — ING CAPITAL GROUP HOLDINGS I*, FIC ING ELECTED I* ING AN COMPANY, LTD. — ELIEMENTAL ING CAPITAL (BEIJING) COMPANY, LTD. C	
		N	

Note 1: HK CC NOMINEE LIMITED, HONG KONG CLEARING COMPANY, LIMITED, N

Note 2: HONG KONG ECIE CLEARING COMPANY LIMITED, HONG KONG CLEARING COMPANY, LIMITED, MB

2.3 The shareholding status of the Top 10 shareholders, including the Top 10 shareholders, C

N

### 3. SIGNIFICANT EVENTS

3.1 **Balance Sheet**

Unit: MB

Balance Sheet				
Items	Closing balance as at the end of the period	Opening balance as at the beginning of the year	Ratio of change	Reasons
Assets	485,549,599.95	198,755,576.52	144.29%	Majorly due to increase in current assets
Accounts receivable		990,340,787.62	-100.00%	(None)
Prepaid expenses	3,494,730.03	11,246,964.92	-68.93%	Majorly due to decrease in prepaid expenses
Accounts payable	3,529,897,004.62	2,499,156,438.67	41.24%	Majorly due to increase in accounts payable
Debt	167,214,321.23	89,379,481.02	87.08%	Majorly due to increase in debt & D
Equity	4,508,065,870.77	2,841,223,392.47	58.67%	Majorly due to increase in equity
Retained earnings	474,418,367.92	342,926,461.15	38.34%	Majorly due to increase in retained earnings
Dividends payable	14,831,357.70	1,279,819.25	1,058.86%	Majorly due to increase in dividends payable
Liabilities		589,118,424.34	-100.00%	(None)
Non-current assets	2,822,255,623.13	1,109,525,523.85	154.37%	Majorly due to increase in non-current assets
Property, plant and equipment	63,116,411.43	1,070,561,681.96	-94.10%	Majorly due to decrease in property, plant and equipment
Intangible assets	1,618,247,844.35	771,191,646.56	109.84%	Majorly due to increase in intangible assets
Bank	1,894,480,886.28	3,085,482,735.30	-38.60%	Majorly due to decrease in bank

Income Statement				
Items	Current amount	Amount of the last period	Ratio of change	Reasons
	Jan - Sep 2015	Jan - Sep 2014		
Revenue	339,686,256.62	251,024,209.33	35.32%	Majorly due to increase in revenue
Accounts receivable	33,340,027.70	11,784,007.60	182.93%	Majorly due to increase in accounts receivable
Goods sold	3,506,487.53	-9,516,778.44	136.85%	Majorly due to increase in goods sold
Non-current assets	63,499,502.52	38,512,060.43	64.88%	Majorly due to increase in non-current assets
Non-current liabilities	10,862,409.73	15,531,263.99	-30.06%	Majorly due to decrease in non-current liabilities
Other	-279,141,519.38	146,057,212.28	-291.12%	Majorly due to decrease in other

Statement of Cash Flow				
Items	Current amount	Amount of the last period	Ratio of change	Reasons
	Jan - Sep 2015	Jan - Sep 2014		
Net cash flow	1,161,951,526.99	843,637,595.71	37.73%	Majorly due to increase in net cash flow
Net cash flow	764,402,303.12	1,793,987,740.16	-57.39%	Majorly due to decrease in net cash flow

Note: I 2014, C 31 D 2014, C L \* (上海星藥業有限公司) (國藥控股國大 美藥業(上海)有限公司), H G D F M C L \* (上海美益星大藥房連鎖有限公司) (國藥控股國大 美大藥房上海連鎖有限公司) B G E M C L \* (北京金象大藥房醫藥連鎖有限責任公司) “A ” “ ” “ ”





(3) ● 16 A 2015, 46  
 B ( )  
 C 2015 ( )  
 C 246,808,510 A MB23.50  
 \* (中國人壽保險股份有限公司),  
 \* (招商財富資產管理有限公司),  
 \* (泰康資產管理有限責任公司),  
 \* (中信建投基金管理有限公司),  
 \* (匯添富基金管理股份有限公司),  
 \* (安徽省鐵路建設投資基金有限公司),  
 \* (北京中融鼎新投資管理有限公司)  
 \* (億利資源控股有限公司).  
 MB5,799,999,985  
 MB3,600,000,000

2014  
 C 21 A 2015,  
 MB23.22  
 249,784,664

● 16 ● 2015, 56  
 B ( )  
 C 2015 ( )  
 A  
 A  
 211,024,978  
 MB4,899,999,989.16.

A  
 C C.

(4) ● 27 A 2015, 55  
 B ( )  
 C MB5  
 7

3.3 [unclear] [unclear] [unclear] C [unclear] [unclear] [unclear] [unclear] 5% [unclear]

Background	Type	Covenantors	Undertakings	Validity period	Whether duration specified	Whether timely and



## 4. APPENDICES

### 4.1 Financial statements

#### Consolidated balance sheet

30 September 2015

上海复星医药(集团)有限公司 : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

货币单位 : 人民币元 (MB)

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
<b>Current Assets:</b>		
流动资产合计	3,516,813,404.78	3,695,698,185.82
货币资金		
应收账款		
预付款项	38,724,495.54	33,770,584.14
其他应收款	408,527,911.80	472,523,132.71
存货	1,789,464,377.02	1,504,149,790.72
流动资产其他项目	136,605,468.61	137,690,114.05
可供出售金融资产		
长期股权投资		
投资性房地产		
固定资产	677,257.70	1,023,889.42
无形资产	16,983,973.47	14,264,402.96
商誉	485,549,599.95	198,755,576.52
长期资产其他项目		
长期股权投资	1,627,321,198.79	1,604,562,390.25
可供出售金融资产		990,340,787.62
无形资产		
商誉	3,494,730.03	11,246,964.92
长期资产其他项目	8,024,162,417.69	8,664,025,819.13
<b>Non-current assets:</b>		
非流动资产合计		
可供出售金融资产	3,529,897,004.62	2,499,156,438.67
长期股权投资		
投资性房地产		
固定资产	13,489,435,775.47	11,905,750,117.54
无形资产		
商誉	4,720,292,409.25	4,623,958,317.63
长期资产其他项目	964,172,888.14	1,051,988,109.53
可供出售金融资产	3,233,982.94	5,450,698.63
长期股权投资		
投资性房地产		
固定资产	2,857,317,020.41	2,822,483,093.20
无形资产	167,214,321.23	89,379,481.02
商誉	3,292,538,591.11	3,255,041,739.55
长期资产其他项目	11,804,369.09	13,583,440.85
可供出售金融资产	92,366,614.48	101,221,671.79
长期股权投资	262,125,551.28	304,238,328.42
投资性房地产	29,390,398,528.02	26,672,251,436.83
固定资产	37,414,560,945.71	35,336,277,255.96

**Consolidated balance sheet (Continued)**

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
<b>Current liabilities:</b>		
	4,508,065,870.77	2,841,223,392.47
B		
D		
L		
F		
B	67,928,606.53	70,987,451.05
	874,465,599.33	833,974,948.21
	226,002,022.22	266,518,255.34
G		
E		
V	296,895,628.48	298,472,746.11
I	474,418,367.92	342,926,461.15
I	166,803,873.32	177,075,081.31
D	14,831,357.70	1,279,819.25
●	1,379,103,280.44	1,935,656,885.83
I		
A		
A		
L		589,118,424.34
N	2,822,255,623.13	1,109,525,523.85
●	63,116,411.43	1,070,561,681.96
	10,893,886,641.27	9,537,320,670.87
<b>Non-current liabilities:</b>		
L	1,618,247,844.35	771,191,646.56
B	1,894,480,886.28	3,085,482,735.30
L	890,883,419.71	710,056,624.65
A		
D	178,123,561.73	139,593,190.51
D	1,934,427,964.42	1,929,331,107.42
●	73,391,869.13	60,299,392.99
	6,589,555,545.62	6,695,954,697.43
	17,483,442,186.89	16,233,275,368.30
<b>Equity:</b>		
( )	2,311,380,364.00	2,311,611,364.00
G	6,049,708,237.59	6,123,454,191.14
L		
●	838,468,407.81	1,120,365,125.73
	1,662,373,054.64	1,662,373,054.64
G		
	6,700,890,376.05	5,457,045,050.64
E		
	17,562,820,440.09	16,674,848,786.15
N	2,368,298,318.73	2,428,153,101.51
	19,931,118,758.82	19,103,001,887.66
	37,414,560,945.71	35,336,277,255.96

Legal Representative:  
**Chen Qiyu**

Chief Financial Officer:  
**Guan Xiaohui**

Director of the Accounting Department:  
**Yan Jia**



## Balance Sheet of the Parent Company (Continued)

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
<b>Current liabilities:</b>		
	1,834,226,000.00	
	78,632,661.11	72,568,579.44
	23,932,653.33	21,842,286.49
	147,159,729.00	160,716,398.26
	1,364,923.50	1,062,450.00
	453,068,674.16	587,606,051.26
	2,641,935,028.99	1,037,216,423.85
		998,894,520.55
	5,180,319,670.09	2,879,906,709.85
<b>Non-current liabilities:</b>		
	186,740,000.00	85,000,000.00
	1,894,480,886.28	3,085,482,735.30
	1,525,000.00	1,750,000.00
	1,209,260,573.79	1,192,857,263.79
	3,292,006,460.07	4,365,089,999.09
	8,472,326,130.16	7,244,996,708.94
<b>Equity:</b>		
	2,311,380,364.00	2,311,611,364.00
	8,227,835,906.44	8,270,816,715.22
	55,747,958.04	224,689,817.57
	949,985,460.52	949,985,460.52
	4,193,926,575.18	2,839,595,396.66
	15,738,876,264.18	14,596,698,753.97
	24,211,202,394.34	21,841,695,462.91

*Legal Representative:*  
**Chen Qiyu**

*Chief Financial Officer:*  
**Guan Xiaohui**

*Director of the Accounting Department:*  
**Yan Jia**



## Consolidated Income Statement

January – September 2015

上海复星医药(集团)有限公司 : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

币种: 人民币 Currencies: MB

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
I. 营业收入	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
I. 营业收入	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
I. 营业收入				
E. 营业收入				
F. 营业收入				
II. 营业成本	2,895,782,154.22	2,841,148,358.80	8,300,064,068.03	8,033,810,333.58
II. 营业成本	1,549,543,653.59	1,718,871,717.37	4,479,008,803.33	4,905,488,021.73
I. 营业成本				
E. 营业成本				
C. 营业成本				
N. 营业成本				
A. 营业成本				
B. 营业成本	24,497,548.36	23,567,831.20	74,510,036.45	59,883,149.42
II. 营业成本	752,785,285.93	589,494,712.71	2,033,469,048.98	1,606,792,320.56
A. 营业成本	439,321,906.97	417,425,034.77	1,340,049,894.95	1,198,838,624.94
F. 营业成本	118,030,107.88	91,347,934.22	339,686,256.62	251,024,209.33
A. 营业成本	11,603,651.49	441,128.53	33,340,027.70	11,784,007.60
G. 营业成本				
H. 营业成本				
I. 营业成本				
J. 营业成本				
K. 营业成本				
L. 营业成本				
M. 营业成本				
N. 营业成本				
O. 营业成本				
P. 营业成本				
Q. 营业成本				
R. 营业成本				
S. 营业成本				
T. 营业成本				
U. 营业成本				
V. 营业成本				
W. 营业成本				
X. 营业成本				
Y. 营业成本				
Z. 营业成本				

## Consolidated Income Statement (Continued)

January – September 2015

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
I.	-503,674,636.21	170,383,244.67	-279,141,519.38	146,057,212.28
	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
(i)				
1.				
2.				
(ii)	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
1.	732,427.55	-9,352.18	-195,739,333.69	-5,108,705.95
2.	-440,970,255.91	171,599,596.74	-16,216,735.14	149,088,050.35
3.				
4.				
5.	-65,806,450.80	-1,851,673.11	-69,940,649.09	3,828,899.96
6.				
	2,369,642.95	644,673.22	2,755,198.54	-1,751,032.08
II.	157,117,103.71	812,100,177.38	1,897,755,696.77	1,940,074,283.26
	81,440,708.74	726,766,676.07	1,609,072,739.39	1,722,392,108.74
	75,676,394.97	85,333,501.31	288,682,957.38	217,682,174.52
III. E				
(1)	0.25	0.24	0.82	0.69
(2)	0.25	0.24	0.82	0.69

Legal Representative:  
**Chen Qiyu**

Chief Financial Officer:  
**Guan Xiaohui**

Director of the Accounting Department:  
**Yan Jia**





## Consolidated Statement of Cash Flow (Continued)

January – September 2015

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
<b>III. Cash flow generated from financing activities:</b>		
G	87,721,195.00	1,445,949,451.00
I	87,721,195.00	38,269,850.07
G	5,110,056,682.54	3,475,109,758.30
G	398,929,000.00	1,000,000,000.00
	40,140,014.05	21,733,509.09
	5,636,846,891.59	5,942,792,718.39
G	3,519,139,442.58	1,623,242,732.68
G	1,114,614,719.91	1,012,768,967.52
I	268,686,768.21	133,554,721.22
	238,690,425.98	1,512,793,278.03
	4,872,444,588.47	4,148,804,978.23
N	764,402,303.12	1,793,987,740.16
<b>IV. Effects of exchange rate fluctuations on cash and cash equivalents</b>	5,949,548.99	14,780,312.38
<b>V. Net increase of cash and cash equivalents</b>		

**Statement of Cash Flow of the Parent Company**  
*January – September 2015*

公司 : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

币种 : 人民币      单位 : 千元

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
<b>I. Cash flow generated from operating activities:</b>		
C <sub>1</sub> 经营活动产生的现金流量	450,000.00	450,000.00
C <sub>2</sub> 经营活动产生的现金流量		
C <sub>3</sub> 经营活动产生的现金流量		
C <sub>4</sub> 经营活动产生的现金流量		
C <sub>5</sub> 经营活动产生的现金流量		
C <sub>6</sub> 经营活动产生的现金流量		
C <sub>7</sub> 经营活动产生的现金流量		
C <sub>8</sub> 经营活动产生的现金流量		
C <sub>9</sub> 经营活动产生的现金流量		
C <sub>10</sub> 经营活动产生的现金流量		
C <sub>11</sub> 经营活动产生的现金流量		
C <sub>12</sub> 经营活动产生的现金流量		
C <sub>13</sub> 经营活动产生的现金流量		
C <sub>14</sub> 经营活动产生的现金流量		
C <sub>15</sub> 经营活动产生的现金流量		
C <sub>16</sub> 经营活动产生的现金流量		
C <sub>17</sub> 经营活动产生的现金流量		
C <sub>18</sub> 经营活动产生的现金流量		
C <sub>19</sub> 经营活动产生的现金流量		
C <sub>20</sub> 经营活动产生的现金流量		
C <sub>21</sub> 经营活动产生的现金流量		
C <sub>22</sub> 经营活动产生的现金流量		
C <sub>23</sub> 经营活动产生的现金流量		
C <sub>24</sub> 经营活动产生的现金流量		
C <sub>25</sub> 经营活动产生的现金流量		
C <sub>26</sub> 经营活动产生的现金流量		
C <sub>27</sub> 经营活动产生的现金流量		
C <sub>28</sub> 经营活动产生的现金流量		
C <sub>29</sub> 经营活动产生的现金流量		
C <sub>30</sub> 经营活动产生的现金流量		
C <sub>31</sub> 经营活动产生的现金流量		
C <sub>32</sub> 经营活动产生的现金流量		
C <sub>33</sub> 经营活动产生的现金流量		
C <sub>34</sub> 经营活动产生的现金流量		
C <sub>35</sub> 经营活动产生的现金流量		
C <sub>36</sub> 经营活动产生的现金流量		
C <sub>37</sub> 经营活动产生的现金流量		
C <sub>38</sub> 经营活动产生的现金流量		
C <sub>39</sub> 经营活动产生的现金流量		
C <sub>40</sub> 经营活动产生的现金流量		
C <sub>41</sub> 经营活动产生的现金流量		
C <sub>42</sub> 经营活动产生的现金流量		
C <sub>43</sub> 经营活动产生的现金流量		
C <sub>44</sub> 经营活动产生的现金流量		
C <sub>45</sub> 经营活动产生的现金流量		
C <sub>46</sub> 经营活动产生的现金流量		
C <sub>47</sub> 经营活动产生的现金流量		
C <sub>48</sub> 经营活动产生的现金流量		
C <sub>49</sub> 经营活动产生的现金流量		
C <sub>50</sub> 经营活动产生的现金流量		